$Lineage Cell Therapeutics(LCTX.US)$Lineage Cell Therapeutics' RG6501 (OpRegen) Phase 1/2a Results Show Evidence of Rapid Improvement of Outer Retinal Structure in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration
$Lineage Cell Therapeutics(LCTX.US)$looking poised for good things to come.. Upward trend Lineage, Genentech Ink Cell Therapy Licensing Pact For Ocular Diseases Benzinga Real-time News · 09:06 Lineage Cell Therapeutics Inc (NYSE:LCTX) has entered into an exclusive worldwide collaboration and license agreement with Roche Holdings AG's (OTC:RHHBY) Genentech to develop and commercialize retinal pigment epithelium (RPE) cell therapy.
Kevin Lehmann : 930am bullish rise friday
Kevin Lehmann : slow pullback till 1130am